Legend Biotech abruptly changed leadership after CEO Ying Huang resigned, with Alan Bash named interim CEO. Legend said a comprehensive search for a permanent replacement is underway and that Huang will remain an advisor through August to support the transition. Bash previously served as president of Carvykti, Legend’s multiple myeloma CAR-T therapy that anchors the company’s commercial base. The leadership move comes as Legend has faced competitive pressure and geopolitical risk considerations tied to its China footprint. For investors, the immediate focus is continuity in Carvykti execution while clinical and regulatory plans remain active, particularly given the sector’s heightened sensitivity to late-stage timelines.